Every material Form 8-K Silence Therapeutics plc has filed with the SEC since August 10, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Silence Therapeutics agreed on October 18, 2026 to be acquired by Merck KGaA, Darmstadt, Germany in an all-cash deal valued at about $1.3 billion in equity value. Shareholders and ADS holders would receive $20.00 in cash per American Depositary Share, a 130% premium to the October 16, 2026 closing ADS price, and the transaction was unanimously approved by the Silence board.
Consideration of $20.00 in cash per ADS, with each ADS representing three ordinary shares ($6.6667 per share)
Equity value of approximately $1.3 billion and enterprise value of $1.1 billion; 82% premium to the 30-day volume-weighted average price of $10.99
Expected close in the first quarter of 2027, subject to shareholder approval, High Court sanction and regulatory approvals; End Date of April 30, 2027
Silence must pay Merck KGaA a $13 million termination fee in certain circumstances; securityholders with about 14% of voting power signed voting and support agreements
Silence Therapeutics plc agreed on August 11, 2026 to sell 12,962,963 American Depositary Shares at $13.50 each in an underwritten public offering, with expected gross proceeds of about $175 million, up from the approximately $150 million announced on August 10. The company expects net proceeds of about $164.0 million, or about $188.7 million if underwriters fully exercise their option, and the offering is expected to close on August 13, 2026, which would add new shares for existing shareholders.
Offering of 12,962,963 ADSs at $13.50 per ADS, with underwriters buying at $12.69 per ADS
Expected net proceeds of about $164.0 million, or about $188.7 million with full exercise of the 30-day option for 1,944,444 additional ADSs
Joint book-running managers are Jefferies LLC and Morgan Stanley & Co. LLC; closing expected on or about August 13, 2026
Silence Therapeutics reported positive topline results from the 36-week Phase 2 SANRECO trial of divesiran in 48 phlebotomy-dependent patients with polycythemia vera, meeting its primary and key secondary endpoints. The company expects to start a Phase 3 trial of divesiran at Q12W dosing versus placebo in the first half of 2027, a step that advances its lead candidate toward potential approval, though the filing reports no revenue, profit or financing figures.
Primary endpoint response rate was 88% for divesiran versus 19% for placebo (p<0.0001)
Mean phlebotomies per patient were 0.2 for divesiran versus 2.1 for placebo over weeks 0-36 (p<0.0001)
Phase 3 trial of divesiran at Q12W versus placebo expected to start in the first half of 2027
Divesiran was well tolerated with no new safety findings; two investigator-reported grade 1 anemia cases
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Silence Therapeutics plc filing is on SEC EDGAR ↗. 8-K briefs of other companies →